Why Saudi biotech sector must involve execution-led strategy 
Saudi Arabia’s biotech ambition is clear, but execution will determine success, not strategy papers or policy intent.
Biotech is not a sector built from advisory tables but by operators and investors with capital at risk.
Execution-led strategy matters because biotech operates under constraints only practitioners fully understand.
Long development timelines, regulatory complexity, and capital intensity are realities that cannot be theorized away.
Those deploying capital on the ground adjust faster than any abstract framework.
“Biotech will not be built by observers but by executors willing to commit capital, carry operational responsibility, and stay through uncertainty.”
The private sector’s role in Saudi Arabia’s biotech industry is therefore foundational, not complementary.
Hands-on investors and operators structure deals, localize technology, build teams, and navigate regulatory pathways.
They are also the first to absorb losses when assumptions fail. This exposure gives them credibility.
Local executors are uniquely positioned to act as ambassadors for Saudi Arabia’s biotech ambition, able to engage foreign direct investors as peers willing to share risk and reward, not as passive recipients of capital.
Foreign investors do not commit to biotech ecosystems based on incentives alone. They follow confidence that local partners understand science, execution, and risk. Early local capital sends a stronger signal than any announcement.
Equally important is peer conviction. Local investors move when persuaded by other practitioners, not promotional narratives.
Builders trust builders; capital follows demonstrated execution.
For Saudi Arabia, empowering executor-led strategy is about effectiveness. When those with skin in the game shape priorities, strategy becomes grounded and resilient.
Biotech will not be built by observers but by executors willing to commit capital, carry operational responsibility, and stay through uncertainty.
• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.
